Letrozole pharmaceutical API powder — CAS 112809-51-5 — WHO-GMP manufacturer Longshine Boi-Tech, Pune, India
Human APIs

Letrozole

CAS Registry Number: 112809-51-5

Letrozole is a third-generation non-steroidal aromatase inhibitor used in the adjuvant and extended-adjuvant treatment of hormone-receptor-positive early breast cancer in postmenopausal women, and increasingly in fertility protocols for ovu

Product information

Letrozole is a third-generation non-steroidal aromatase inhibitor used in the adjuvant and extended-adjuvant treatment of hormone-receptor-positive early breast cancer in postmenopausal women, and increasingly in fertility protocols for ovulation induction. Manufactured to USP and Ph. Eur. specifications with rigorous polymorph and impurity control.

Product specifications

CAS Registry Number
112809-51-5
Therapeutic Category
Human APIs
API Technology
Synthetic / Semi-synthetic (per molecule)
Development Status
Commercial — stocked
Manufacturer
Longshine Boi-Tech Pvt. Ltd.
Facility
Pune, Maharashtra, India 411001

Regulatory filings & documentation

We maintain regulatory dossiers in the following jurisdictions for Letrozole-relevant molecules. Letter of Authorization (LoA) and CEP / DMF / ASMF references are issued at no charge to qualified buyers.

US FDA DMF (Type II)
EDQM CEP (where applicable)
Brazil ANVISA
Canada Health Canada
Japan PMDA
Korea MFDS
GCC SFDA
EU CEP
WHO-GMP & ISO 9001:2015 certified. US FDA Drug Master File available. EDQM CEP supplied for EU procurement. Pharmacopoeial release against USP, Ph. Eur., IP, JP. CoA on every batch. First-shipment lead time 7-10 business days for stocked APIs.
View interactive page & request quote Email sales Order a sample

Frequently asked questions about Letrozole

What is Letrozole used for?

Letrozole is supplied as a pharmaceutical-grade human apis for use by regulated pharmaceutical manufacturers, contract development and manufacturing organisations (CDMOs), and research institutions. Buyers using Letrozole typically reference it under CAS Registry Number 112809-51-5.

What quality and regulatory standards does Longshine Boi-Tech's Letrozole meet?

Our Letrozole is manufactured under WHO-GMP and ISO 9001:2015 conditions in Pune, India. Per-batch Certificate of Analysis (CoA) is released against USP / Ph. Eur. / IP / JP specifications depending on destination market. We hold US FDA Drug Master File and EDQM Certificate of Suitability dossiers for the molecules where regulatory recognition is required; Letter of Authorization (LoA) is issued at no charge to qualified buyers.

How do I request a quote, sample, or proforma invoice for Letrozole?

Quote requests for Letrozole are turned around within 24 business hours (IST, Pune). Bulk APIs typically ship within 7-10 business days of confirmed PO; air freight to North America and Europe runs 4-5 days door-to-door. Sample agreements are signed before shipping QC-grade material to your formulation laboratory.

Which countries does Longshine Boi-Tech supply Letrozole to?

We export Letrozole to 50+ countries including the United States, Canada, Mexico, Brazil, the European Union, the United Kingdom, Japan, Australia, South Korea, the GCC and across South-East Asia. All regulatory documents (DMF / CEP / LoA) and shipping incoterms (EXW, FCA, CIP, DAP, DDP) are negotiated per buyer.

Related Human APIs APIs

Other human apis molecules from Longshine Boi-Tech's WHO-GMP catalogue — each with active regulatory filings, audit-ready CoA, and samples available under CDA.

Linagliptin
CAS 668270-12-0
Abacavir Sulfate
CAS 188062-50-2
Azithromycin Dihydrate
CAS 117772-70-0
Irinotecan HCl
CAS 100286-90-6
Empagliflozin
CAS 864070-44-0
Rosuvastatin Calcium
CAS 147098-20-2
Telmisartan
CAS 144701-48-4
Tenofovir Disoproxil Fumarate
CAS 202138-50-9

Related categories & resources

Browse the full Human APIs catalogue or all 560+ products. Reference documents: certifications portfolio · quality system · FDA DMF buyer guide · EU CEP supplier guide · complete product index.